Assessment of renal and hepatic tissue-protective effects of n-acetylcysteine via ammonia metabolism: A prospective randomized study

ArticleAçık Erişim

Özet

Background: The present study sought to assess the renal and liver protective effect of N-acetylcysteine through NH3 and urea metabolism in patients with chronic obstructive pulmonary disease who were scheduled for coronary artery bypass grafting surgery. Material/Methods: Patients with chronic obstructive pulmonary disease (COPD) who were scheduled for coronary artery bypass grafting were divided into 2 groups so as to receive (Group 1, n=35) or not receive (Group 2, n=35) 900 mg/day of n-acetylcysteine for 7 days before the operation starting from their admission to the service by a pulmon-ologist with the purpose of treating COPD until the day of surgery. Both groups were subjected to the same anesthesia protocol. Blood samples were taken preoperatively, within the first 15th minute following cessation of the cardiopulmonary bypass, at postoperative 24th hour, and at postoperative 48th hour. Blood tests included ammonia (NH3), lactate, blood urea nitrogen, creatinine, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), troponin I (Tn I), and creatinine kinase-muscle brain (CKMB). Results: There was a significant difference between the groups’ NH3 and lactate levels after cardiopulmonary bypass, postoperative 24th hour, and postoperative 48th hour (respectively, NH3: 39.0±8.8 vs. 55.4±19.6 and 40.1±8.4 vs. 53.2±20.2 mcg/dl, lactate: 1.7±0.9 vs. 2.1±1.2 and 1.2±0.5 vs. 1.8±1.4 mmol/L; p<0.01). Creatinine and BUN levels in Group 2 were found to be significantly higher at the postoperative 48th hour compared to the levels of Group 1 (P<0.05). Conclusions: N-acetylcysteine pretreatment appears to improve renal and hepatic functions through regulation of ammonia and nitrogen metabolism and reduction of lactate in patients with chronic obstructive pulmonary disease who undergo coronary artery bypass grafting surgery. We found that N-acetylcysteine improved kidney and/or liver functions. © Med Sci Monit.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14107Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.12659/msm.908172Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorOnk, Didem
dc.contributor.authorÖzçelik, Fatih
dc.contributor.authorOnk, Oruç Alper
dc.contributor.authorGünay, Murat
dc.contributor.authorAyazoğlu, Tülin Akarsu
dc.contributor.authorÜnver, Ethem
dc.date.accessioned2026-10-18T20:28:53.416797373Z
dc.date.available2026-10-18T20:28:53.416797373Z
dc.date.issued2018
dc.description.abstractBackground: The present study sought to assess the renal and liver protective effect of N-acetylcysteine through NH3 and urea metabolism in patients with chronic obstructive pulmonary disease who were scheduled for coronary artery bypass grafting surgery. Material/Methods: Patients with chronic obstructive pulmonary disease (COPD) who were scheduled for coronary artery bypass grafting were divided into 2 groups so as to receive (Group 1, n=35) or not receive (Group 2, n=35) 900 mg/day of n-acetylcysteine for 7 days before the operation starting from their admission to the service by a pulmon-ologist with the purpose of treating COPD until the day of surgery. Both groups were subjected to the same anesthesia protocol. Blood samples were taken preoperatively, within the first 15th minute following cessation of the cardiopulmonary bypass, at postoperative 24th hour, and at postoperative 48th hour. Blood tests included ammonia (NH3), lactate, blood urea nitrogen, creatinine, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), troponin I (Tn I), and creatinine kinase-muscle brain (CKMB). Results: There was a significant difference between the groups’ NH3 and lactate levels after cardiopulmonary bypass, postoperative 24th hour, and postoperative 48th hour (respectively, NH3: 39.0±8.8 vs. 55.4±19.6 and 40.1±8.4 vs. 53.2±20.2 mcg/dl, lactate: 1.7±0.9 vs. 2.1±1.2 and 1.2±0.5 vs. 1.8±1.4 mmol/L; p<0.01). Creatinine and BUN levels in Group 2 were found to be significantly higher at the postoperative 48th hour compared to the levels of Group 1 (P<0.05). Conclusions: N-acetylcysteine pretreatment appears to improve renal and hepatic functions through regulation of ammonia and nitrogen metabolism and reduction of lactate in patients with chronic obstructive pulmonary disease who undergo coronary artery bypass grafting surgery. We found that N-acetylcysteine improved kidney and/or liver functions. © Med Sci Monit.
dc.identifier.doi10.12659/msm.908172
dc.identifier.eissn1643-3750
dc.identifier.endpage1546
dc.identifier.issn1234-1010
dc.identifier.pmcidPMC5866733
dc.identifier.pmid29540661
dc.identifier.scopus2-s2.0-85044568855
dc.identifier.startpage1540
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14107
dc.identifier.volume24
dc.identifier.wosWOS:000427522900001
dc.language.isoen
dc.publisherInternational Scientific Information, Inc.
dc.relation.ispartofMedical Science Monitor
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcetylcysteine
dc.subjectChronic Obstructive
dc.subjectCoronary Artery Bypass
dc.subjectPulmonary Disease
dc.subjectAdult
dc.subjectAmmonia
dc.subjectBlood Urea Nitrogen
dc.subjectFemale
dc.subjectHumans
dc.subjectKidney
dc.subjectLactic Acid
dc.subjectLiver
dc.subjectMale
dc.subjectalanine aminotransferase
dc.subjectalkaline phosphatase
dc.subjectaspartate aminotransferase
dc.subjectcreatine kinase MB
dc.subjectcreatinine
dc.subjectglucose
dc.subjecttroponin I
dc.subjectArticle
dc.subjectblood sampling
dc.subjectbody mass
dc.subjectchronic obstructive lung disease
dc.subjectcontrolled study
dc.subjectcoronary artery bypass graft
dc.subjecthematocrit
dc.subjecthuman
dc.subjectkidney function
dc.subjectleukocyte count
dc.titleAssessment of renal and hepatic tissue-protective effects of n-acetylcysteine via ammonia metabolism: A prospective randomized study
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus12
rdl.citation.wos8
rdl.departmentDepartment of Anesthesiology, Faculty of Medicine, Erzincan University, Erzincan, Turkey. | Department of Cardiovascular Surgery, Faculty of Medicine, Erzincan University, Erzincan, Turkey. | Department of Biochemistry, Faculty of Medicine, Erzincan University, Erzincan, Turkey. | Department of Chest Diseases, Faculty of Medicine, Erzincan University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)